P2RX7 and rheumatoid arthritis: Potential P2X7 receptor inhibitors developed by AstraZeneca (AZD9056) and Pfizer (CE-224535) have been tested in a clinical trial for rheumatoid arthritis, which potently inhibits ATP-P2X7-induced IL-1β and IL-18 releases in the patient [225,226].